A dire wolf de-extinction debate, CRISPR-GPT for gene editing, and more topped the list of our most popular stories in ...

Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

CRISPR Therapeutics (NASDAQ: CRSP) soared a few years ago, climbing more than 200% from the start of 2020 through early 2021, ...

The popular nursery rhyme This Little Piggy is an early childhood memory for many of us. It’s a poem that involves five little piggies, each corresponding to one of our fingers or toes. Kids love it, ...

Goldenberries have long been a niche curiosity, tucked into specialty produce aisles and health food shops while tomatoes and ...

It was the best of times, it was the worst of times for research in 2025. | It was the best of times and it was the worst of times for research in 2025. Medical breakthroughs and stunning discoveries ...

O 15, 2025, Barclays analyst Luke Sergott raised the price target for TXG from $17 to $22 while maintaining an Overweight ...

Against this backdrop, a research team led by Dr. Guozhang Kang and Dr. Gezi Li from Henan Agricultural University, China, ...

Now, Musunuru and colleagues are preparing a master clinical protocol to study a CRISPR therapy that's mostly the same as the one they used to treat baby KJ, except they plan to swap out the gene ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, ...